US8846033B2 - Dietary supplement - Google Patents

Dietary supplement Download PDF

Info

Publication number
US8846033B2
US8846033B2 US12/452,759 US45275908A US8846033B2 US 8846033 B2 US8846033 B2 US 8846033B2 US 45275908 A US45275908 A US 45275908A US 8846033 B2 US8846033 B2 US 8846033B2
Authority
US
United States
Prior art keywords
lactase
amylase
bromelain
dietary
concentrated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/452,759
Other versions
US20100143320A1 (en
Inventor
Christian Chossade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ET and DS Co Ltd
Original Assignee
ET and DS Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ET and DS Co Ltd filed Critical ET and DS Co Ltd
Assigned to ET & DS COMPANY LTD. reassignment ET & DS COMPANY LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOSSADE, CHRISTIAN
Publication of US20100143320A1 publication Critical patent/US20100143320A1/en
Application granted granted Critical
Publication of US8846033B2 publication Critical patent/US8846033B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A23L1/305—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A23L1/3055—
    • A23L1/3056—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Definitions

  • the present invention relates to digestion essentially of milk proteins, but also to other proteins absorbed in a large amount and repeatedly. It relates to a dietary supplement promoting proper ingestion and proper digestion of animal and/or vegetable proteins, and consisting of a mixture of enzymes comprising amylase, lactase and bromelain.
  • lactase is deficient in a large portion of the world adult population. This enzyme, present in newborns for digesting maternal milk, gradually disappears after weaning. Continued consumption of milk amounts to maintaining the lactase slightly active, but this is going against nature. The production is forced of an enzyme in principle intended to disappear.
  • Lactase belongs to the brush-border of enterocytes, which are the cells making up the wall of the intestine. Now, when the activity of the lactase is insufficient, lactose accumulates and passes into the large intestine where it is fermented by colic flora, in the same way as other absorbed proteins, either in large amounts or without lipids and/or carbohydrates. This causes the symptoms described above. Insufficient production of lactase by the body in addition to the consequences described above, may also generate more serious disorders.
  • amylase the second constituent of the invention—is an enzyme, notably with which starch and dextrins may be digested by transforming them into assimilable reducing sugars. It is secreted by the pancreas and salivary glands. It is possible to increase the amount of amylase in the organism when either one of these glands is defective.
  • One of the major benefits in the perspective of promoting digestion is that it increases the amount of saliva in the mouth and the work of reducing the foodstuffs may thereby be started. It avoids the “dead weight” feeling due to ingested proteins.
  • a too large absorption of amylase however results in an abnormal increase in the level of triglycerides. This may cause chronic pancreatitises, cholecystitises, cysts, ulcer perforations of the duodenum or peritonitises, notably in the case of absorption of animal enzymes. Its dosage is therefore important.
  • the third constituent of the dietary supplement of the invention bromelain moreover known and used in treating venous diseases, contusions, arthritis, rheumatoid arthritis, and gout, also allows total reduction of proteins and of its components, by however acting less rapidly than lactose and amylase. Therefore it completes their action. It is also used in Europe for promoting recovery after an operation or sports injuries or for treating sinusitises or phlebitises.
  • the object of the invention aims at producing a dietary supplement ensuring proper buccal absorption on the one hand and digestion without any disorders on the other hand, while however avoiding potential secondary effects due to its constituents.
  • the dietary supplement of the invention is indicated in the case of difficulties related to digestion of any type of proteins, regardless of the vegetable or animal origin of the latter. First, it allows an increase in the lactase content of the body for the purposes of proper digestion, but also allows different placement in the mouth (buccal ingestion of foodstuff) by associating lactase with amylase.
  • lactase association of bromelain with amylase and with lactase promotes digestion without any bothersome or undesired secondary effects.
  • Dosage of lactase is particularly important because with such a dosage which may be described as being a low as possible in order to avoid detrimental effects on the blood stream, even in the case of ingestion over a long period. Secondary effects possibly caused by a high dosage of lactase are thereby avoided.
  • the amounts of the different enzymes may more specifically be:
  • the provided amounts are of the order of:
  • the invention relates to a concentrated protein food product, supplemented by means of a dietary supplement as shown above.
  • said protein concentrate has a protein content greater than 82%.
  • the concentrated proteins may be of animal origin. According to an alternative, they may also be of vegetable origin or further result from a mixture of both.
  • an amylase of vegetable origin and a lactase of vegetable and/or animal origin are used.
  • An undeniable advantage of the dietary supplement according to the invention therefore lies for a large part in the interaction of amylase, lactase and bromelain, each with a low dose.

Abstract

The invention relates to a dietary supplement that promotes proper ingestion and proper digestion of animal and/or vegetable proteins. The supplement comprises an enzyme mixture containing amylase, lactase and bromelain in the following dosage by weight: 15 mg to 90 mg amylase, 18 mg to 90 mg lactase and 6 mg to 80 mg bromelain.

Description

The present invention relates to digestion essentially of milk proteins, but also to other proteins absorbed in a large amount and repeatedly. It relates to a dietary supplement promoting proper ingestion and proper digestion of animal and/or vegetable proteins, and consisting of a mixture of enzymes comprising amylase, lactase and bromelain.
Digestion of milk protein in particular poses a problem in many respects. Thus, certain persons are unable to retain within their body a particular enzyme, lactase which is used for digesting lactose contained in dairy products. In fact they are intolerant to lactose. When these persons consume dairy products, they suffer from ailments, such as vomiting, flatulence, halitosis, cramps or other intestinal disorders of the diarrhea type, etc.
In fact, lactase is deficient in a large portion of the world adult population. This enzyme, present in newborns for digesting maternal milk, gradually disappears after weaning. Continued consumption of milk amounts to maintaining the lactase slightly active, but this is going against nature. The production is forced of an enzyme in principle intended to disappear.
Under the assumption of a lack of congenital or acquired lactase production, the subject is therefore intolerant to lactose, intolerance resulting from a reaction of the body to consumed milk.
Lactase belongs to the brush-border of enterocytes, which are the cells making up the wall of the intestine. Now, when the activity of the lactase is insufficient, lactose accumulates and passes into the large intestine where it is fermented by colic flora, in the same way as other absorbed proteins, either in large amounts or without lipids and/or carbohydrates. This causes the symptoms described above. Insufficient production of lactase by the body in addition to the consequences described above, may also generate more serious disorders.
It is therefore not sufficient to supplement the body with lactase in order to avoid the digestive disorders described above, since a poorly dosed provision over a too long period generates other risks, for example poor blood circulation.
With reference to the problem related to digestion which is solved by the invention, amylase—the second constituent of the invention—is an enzyme, notably with which starch and dextrins may be digested by transforming them into assimilable reducing sugars. It is secreted by the pancreas and salivary glands. It is possible to increase the amount of amylase in the organism when either one of these glands is defective.
One of the major benefits in the perspective of promoting digestion is that it increases the amount of saliva in the mouth and the work of reducing the foodstuffs may thereby be started. It avoids the “dead weight” feeling due to ingested proteins.
A too large absorption of amylase however results in an abnormal increase in the level of triglycerides. This may cause chronic pancreatitises, cholecystitises, cysts, ulcer perforations of the duodenum or peritonitises, notably in the case of absorption of animal enzymes. Its dosage is therefore important.
Always in the same digestive perspective, the third constituent of the dietary supplement of the invention, bromelain moreover known and used in treating venous diseases, contusions, arthritis, rheumatoid arthritis, and gout, also allows total reduction of proteins and of its components, by however acting less rapidly than lactose and amylase. Therefore it completes their action. It is also used in Europe for promoting recovery after an operation or sports injuries or for treating sinusitises or phlebitises.
At a high dose, it however causes secondary effects such as vomiting and severe kidney failure, and its dosage should therefore be measured with great care.
The object of the invention aims at producing a dietary supplement ensuring proper buccal absorption on the one hand and digestion without any disorders on the other hand, while however avoiding potential secondary effects due to its constituents.
In other words, the dietary supplement of the invention should promote proper ingestion and proper digestion of animal and/or vegetable proteins. For this purpose, according to the invention, the mixture of enzymes based on the combination of amylase, lactase and bromelain, should observe the following weight dosage:
    • 15 mg-90 mg for amylase,
    • 18 mg-90 mg for lactase; and
    • 6 mg-80 mg for bromelain.
The use of these enzymes is mainly of interest insofar that it may accelerate chemical and biochemical reactions which occur during digestion. These enzymes thus have the role of a catalyst in the human body.
The dietary supplement of the invention is indicated in the case of difficulties related to digestion of any type of proteins, regardless of the vegetable or animal origin of the latter. First, it allows an increase in the lactase content of the body for the purposes of proper digestion, but also allows different placement in the mouth (buccal ingestion of foodstuff) by associating lactase with amylase.
Finally, association of bromelain with amylase and with lactase promotes digestion without any bothersome or undesired secondary effects. Dosage of lactase is particularly important because with such a dosage which may be described as being a low as possible in order to avoid detrimental effects on the blood stream, even in the case of ingestion over a long period. Secondary effects possibly caused by a high dosage of lactase are thereby avoided.
With the aforementioned dosage of amylase, between 15 and 90 mg, it is also possible to avoid any risk of complication related to prolonged taking, while providing the previously explained contribution to digestion of proteins.
The use of bromelain, in an amount between 6 mg and 80 mg, may provide a significant benefit to digestion and does not generate any secondary effect in the case of ingestion over a long period.
Many applications of the dietary supplement of the invention are possible.
Thus, according to one example, for a dietary supplement notably intended for sports(wo)men, the amounts of the different enzymes may more specifically be:
    • 30 mg for amylase,
    • 40 mg for lactase; and
    • 15 mg for bromelain.
For another application intended for a more dietetic use, the provided amounts are of the order of:
    • 40 mg for amylase,
    • 60 mg for lactase; and
    • 25 mg for bromelain.
According to the invention, the dietary supplement either added or not to other ingredients, may appear in all the possible galenic forms, i.e.: powder or granules to be re-hydrated or to be consumed as such, pills, tablets, gelatin capsules, but also in a liquid or pasty presentation. These forms or presentations are not exhaustive.
Moreover, the invention relates to a concentrated protein food product, supplemented by means of a dietary supplement as shown above. Preferably, said protein concentrate has a protein content greater than 82%.
Digestion of hyperprotein foodstuffs of any type may be facilitated by such a concentrated and supplemented food product. The latter secondarily promotes draining and elimination of fats in sports(wo)men, as well as enrichment of the muscular mass.
Moreover, spectacular results may be obtained for resorbing fats in obese persons.
In such a product, the concentrated proteins may be of animal origin. According to an alternative, they may also be of vegetable origin or further result from a mixture of both.
Preferably, according to the invention, an amylase of vegetable origin and a lactase of vegetable and/or animal origin are used.
According to the conducted tests, by associating amylase, lactase and bromelain with dosages comprised in the intervals indicated earlier, i.e. 15-90 mg for amylase, 18-90 mg for lactase and 6-80 mg for bromelain, a significant and reliable result in improving digestion of proteins may be obtained. The association of these dosages—which may be described as low—of enzymes is therefore unexpectedly, particularly indicated in the treatment of digestive problems.
The results related to the association of these three enzymes at a low dosage are all the more remarkable since their use was hitherto known only at strong or high dosages for obtaining a significant result in digestion, with the risk of bothersome, secondary effects, or even dangerous effects in certain cases. The particularly interesting results obtained in digestion of proteins cannot in any case be observed with taking any one of the previous enzymes individually with a dosage as indicated.
An undeniable advantage of the dietary supplement according to the invention therefore lies for a large part in the interaction of amylase, lactase and bromelain, each with a low dose.

Claims (20)

The invention claimed is:
1. A concentrated protein dietary product, supplemented by means of a dietary supplement, comprising:
a concentrated protein food product having a protein content greater than 82%; and
a dietary supplement promoting proper ingestion and proper digestion of animal and/or vegetable proteins added to the concentrated protein food product, the dietary supplement consisting of a mixture of enzymes consisting essentially of amylase, lactase, and bromelain,
wherein the weight dosage of amylase, lactase, and bromelain is:
15 mg to 90 mg for amylase,
18 mg to 90 mg for lactase, and
6 mg to 80 mg for bromelain.
2. The concentrated protein dietary product according to claim 1, wherein the proteins of the concentrated protein food product are of animal origin.
3. The concentrated protein dietary product according to claim 1, wherein the proteins of the concentrated protein food product are of vegetable origin.
4. The concentrated protein dietary product according to claim 1, wherein the weight dosage of amylase, lactase, and bromelain is:
30 mg for amylase,
40 mg for lactase, and
15 mg for bromelain.
5. The concentrated protein dietary product according to claim 1, wherein the weight dosage of amylase, lactase, and bromelain is:
40 mg for amylase,
60 mg for lactase, and
25 mg for bromelain.
6. The concentrated protein dietary product according to claim 1, wherein the concentrated protein dietary product is added to a hyperprotein foodstuff.
7. A supplemented dietary product comprising:
a dietary product containing animal and/or vegetable proteins; and
a dietary supplement promoting proper ingestion and proper digestion of animal and/or vegetable proteins added to the dietary product, the dietary supplement consisting of a mixture of enzymes consisting essentially of amylase, lactase, and bromelain,
wherein the weight dosage of amylase, lactase, and bromelain is:
15 mg to 90 mg for amylase,
18 mg to 90 mg for lactase, and
6 mg to 80 mg for bromelain.
8. The supplemented dietary product of claim 7, wherein the weight dosage of amylase, lactase, and bromelain is:
30 mg for amylase,
40 mg for lactase, and
15 mg for bromelain.
9. The supplemented dietary product of claim 7, wherein the weight dosage of amylase, lactase, and bromelain is:
40 mg for amylase,
60 mg for lactase, and
25 mg for bromelain.
10. The supplemented dietary product of claim 7, wherein the proteins are of animal origin.
11. The supplemented dietary product of claim 7, wherein the proteins are of vegetable origin.
12. A method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins, the method comprising ingesting the supplemented dietary product of claim 7.
13. The method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins according to claim 12, wherein the weight dosage of amylase, lactase, and bromelain is:
30 mg for amylase,
40 mg for lactase, and
15 mg for bromelain.
14. The method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins according to claim 12, wherein the weight dosage of amylase, lactase, and bromelain is:
40 mg for amylase,
60 mg for lactase, and
25 mg for bromelain.
15. The method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins according to claim 12, wherein the proteins are of animal origin.
16. The method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins according to claim 12, wherein the proteins are of vegetable origin.
17. A concentrated protein dietary product, supplemented by means of a dietary supplement, comprising:
a concentrated protein food product having a protein content greater than 82%; and
a dietary supplement promoting proper ingestion and proper digestion of animal and/or vegetable proteins added to the concentrated protein food product, the dietary supplement consisting of a mixture of enzymes comprising amylase, lactase, and bromelain,
wherein the weight dosage of amylase, lactase, and bromelain is:
15 mg to 30 mg for amylase,
18 mg to 90 mg for lactase, and
6 mg to 80 mg for bromelain.
18. The concentrated protein dietary product according to claim 17, wherein the weight dosage of amylase, lactase, and bromelain is:
30 mg for amylase,
40 mg for lactase, and
15 mg for bromelain.
19. A method of promoting proper ingestion and proper digestion of animal and/or vegetable proteins, the method comprising ingesting the concentrated protein dietary product of claim 17.
20. The concentrated protein dietary product according to claim 17, wherein the concentrated protein dietary product is added to a hyperprotein foodstuff.
US12/452,759 2007-06-18 2008-06-16 Dietary supplement Active 2030-10-31 US8846033B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07360026.4A EP2016838B1 (en) 2007-06-18 2007-06-18 Food supplement
EP07360026 2007-06-18
EP07360026.4 2007-06-18
PCT/FR2008/051071 WO2009004238A2 (en) 2007-06-18 2008-06-16 Dietary supplement

Publications (2)

Publication Number Publication Date
US20100143320A1 US20100143320A1 (en) 2010-06-10
US8846033B2 true US8846033B2 (en) 2014-09-30

Family

ID=38645874

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/452,759 Active 2030-10-31 US8846033B2 (en) 2007-06-18 2008-06-16 Dietary supplement

Country Status (15)

Country Link
US (1) US8846033B2 (en)
EP (1) EP2016838B1 (en)
CA (1) CA2707433C (en)
CY (1) CY1119462T1 (en)
EA (1) EA011620B1 (en)
ES (1) ES2636449T3 (en)
LT (1) LT2016838T (en)
MA (1) MA31509B1 (en)
NO (1) NO342468B1 (en)
PL (1) PL2016838T3 (en)
PT (1) PT2016838T (en)
SI (1) SI2016838T1 (en)
UA (1) UA92197C2 (en)
WO (1) WO2009004238A2 (en)
ZA (1) ZA201000236B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4121C1 (en) * 2010-09-16 2012-02-29 Inst De Microbiologie Si Biotehnologie Al Academiei De Stiinte A Moldovei Process for the production of cellulase-amylase complex
WO2014130007A1 (en) * 2013-02-19 2014-08-28 Deerland Enzymes, Inc. Proteolytic compositions for rapidly and extensively degrading protein supplements
CA2997401C (en) * 2015-09-21 2023-06-13 Dsm Ip Assets B.V. Yeast cell wall derived flavour

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079125A (en) 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5569458A (en) 1994-09-14 1996-10-29 Greenberg; Mike Nutritional formula
US5902617A (en) 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
US20030059498A1 (en) * 1999-12-09 2003-03-27 Finnfeeds International Limited Additive for an animal feed
US20040253295A1 (en) 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20050112176A1 (en) * 2002-12-20 2005-05-26 Dopson Minter H. Nutritional supplement composition and method
WO2006060414A2 (en) 2004-12-01 2006-06-08 Kirkman Group, Inc. Compositions and methods for the treatment of autism
US20060280840A1 (en) * 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
DE20220180U1 (en) * 2002-12-31 2003-04-03 Complen Vertriebs Gmbh Multivitamin food supplement including minerals, trace elements, fatty acids and natural materials has high vital ingredients content while showing minimal calorific loading
DE10321725A1 (en) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzyme-containing compositions, dietetic foods and pharmaceuticals made therefrom and their use for medical purposes

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079125A (en) 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US5902617A (en) 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5569458A (en) 1994-09-14 1996-10-29 Greenberg; Mike Nutritional formula
US20030059498A1 (en) * 1999-12-09 2003-03-27 Finnfeeds International Limited Additive for an animal feed
US20040253295A1 (en) 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20050112176A1 (en) * 2002-12-20 2005-05-26 Dopson Minter H. Nutritional supplement composition and method
WO2006060414A2 (en) 2004-12-01 2006-06-08 Kirkman Group, Inc. Compositions and methods for the treatment of autism
US20060280840A1 (en) * 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Search Report for International Application No. PCT/FR2008/051071, issued Feb. 11, 2009.

Also Published As

Publication number Publication date
PT2016838T (en) 2017-08-28
EA200801356A1 (en) 2008-12-30
SI2016838T1 (en) 2018-01-31
NO342468B1 (en) 2018-05-28
EP2016838A3 (en) 2009-08-05
US20100143320A1 (en) 2010-06-10
NO20100060L (en) 2010-02-10
CA2707433C (en) 2016-04-19
MA31509B1 (en) 2010-07-01
EP2016838B1 (en) 2017-05-31
CY1119462T1 (en) 2018-03-07
WO2009004238A2 (en) 2009-01-08
CA2707433A1 (en) 2009-01-08
LT2016838T (en) 2017-11-10
PL2016838T3 (en) 2018-01-31
WO2009004238A3 (en) 2009-04-09
ZA201000236B (en) 2010-09-29
UA92197C2 (en) 2010-10-11
ES2636449T3 (en) 2017-10-05
EP2016838A2 (en) 2009-01-21
EA011620B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
Sardesai Introduction to clinical nutrition
US20040253227A1 (en) Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
JP2019516775A (en) Composition of probiotics and digestive enzymes, method of preparation and use thereof
CN103518843A (en) Soybean peptide solid beverage
AU2015310517A1 (en) Optimized nutrient food
CN103751327A (en) Zinc gluconate VC (Vitamin C) effervescent tablet
US20240108050A1 (en) Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid
US8846033B2 (en) Dietary supplement
CN103371318A (en) Dietary nutrition replenishing food
CN108703376A (en) A kind of short peptide type many polymerizers of the EA
CN103431411A (en) Milk calcium orally fast dissolving tablet convenient to be taken by infants and production method thereof
CN105996057A (en) Fruit and egg white peptide tablets and preparing method thereof
CN108851037A (en) A kind of preparation method and its usage of nephrotic syndrome wholefood
KR20060024766A (en) Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
Nhan et al. Plant-based diets: a fad or the future of medical nutrition therapy for children with chronic kidney disease?
CN102511860B (en) Thickened red jujube pulp added with phytosterin and being suitable for being taken by pregnant women
ES2302396B1 (en) FUNCTIONAL FOOD BASED ON A LIQUID FERMENTED LACQUER PRODUCT AND CONJUGATED LYNOLEIC ACID.
CN106579332A (en) Starch conditioner for food sweetening and digestion promoting
Park et al. Digestive enzyme supplementation in prescription drugs, over-the-counter drugs, and enzyme foods
ES2299288B1 (en) FUNCTIONAL FOOD BASED ON A NON-FERMENTED DAIRY PRODUCT COMBINED WITH FRUIT JUICE AND CONJUGATED LINOLEIC ACID.
Shukla et al. Lactonova Happi gummy Digestive Enzymes: Helps to relief from occasional bloating & intestinal discomfort
CA3230687A1 (en) Fungal enzyme mixtures and uses thereof
JP4268165B2 (en) A method for producing dietary supplements with proven efficacy
CN105231454A (en) Manufacturing method of health-preserving ferment
Patel The Effects of Combinations of Digestive Enzymes and Probiotics on the Production of Glucose from a Variety of Grains

Legal Events

Date Code Title Description
AS Assignment

Owner name: ET & DS COMPANY LTD.,CYPRUS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHOSSADE, CHRISTIAN;REEL/FRAME:023845/0448

Effective date: 20100113

Owner name: ET & DS COMPANY LTD., CYPRUS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHOSSADE, CHRISTIAN;REEL/FRAME:023845/0448

Effective date: 20100113

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8